MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00099346|
Recruitment Status : Terminated
First Posted : December 13, 2004
Last Update Posted : June 17, 2015
Study with an investigational drug in patients with recurrent or non-responsive colorectal cancer or other advanced solid tumors.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Advanced Solid Tumors||Drug: MK0457, VX-680 (Aurora Kinase Inhibitor)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors|
|Study Start Date :||January 2005|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099346
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|